Suppr超能文献

检查淋巴结数量作为pT1N+或pT2-3N0期胃癌复发的危险因素

Number of Examined Lymph Nodes as a Risk Factor for Recurrence in pT1N+ or pT2-3N0 Gastric Cancer.

作者信息

Nishimuta Masato, Arai Junichi, Hamasaki Keiko, Hashimoto Yasumasa, Nonaka Takashi, Tominaga Tetsuro, Oyama Shosaburo, Yasutake Toru, Sawai Terumitsu, Nagayasu Takeshi

机构信息

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.

出版信息

Cancer Diagn Progn. 2022 Sep 3;2(5):558-563. doi: 10.21873/cdp.10142. eCollection 2022 Sep-Oct.

Abstract

BACKGROUND/AIM: Japanese Gastric Cancer Treatment Guidelines do not recommend adjuvant chemotherapy after radical gastrectomy for pathological stage (p) T1N+ or pT2~3N0 gastric cancer. However, some patients experience disease recurrence. This study aimed to identify the risk factors for recurrence in pT1N+ or pT2-3N0 gastric cancer.

PATIENTS AND METHODS

The study included 157 patients with diagnosed pT1N+ or pT2-3N0 gastric cancer who underwent radical gastrectomy at our institution between January 2001 and December 2020. Clinicopathological data and surgical data were obtained. Independent prognostic factors were analyzed using a Cox proportional hazards regression model.

RESULTS

Thirteen patients (8.3%) experienced disease recurrence. Multivariate analysis revealed that the number of examined lymph nodes was an independent prognostic factor for recurrence-free survival (hazard ratio=10.90; 95% confidence interval=1.39-85.86; p=0.023). The group with ≤35 examined lymph nodes had significantly worse recurrence-free survival compared with the group with ≥36 examined lymph nodes (80.7% versus 98.7%; p=0.0005).

CONCLUSION

The number of examined lymph nodes (≤35) was an independent risk factor for recurrence after radical gastrectomy with pT1N+ or pT2-3N0 gastric cancer.

摘要

背景/目的:日本胃癌治疗指南不推荐对病理分期为(p)T1N+或pT2~3N0的胃癌患者在根治性胃切除术后进行辅助化疗。然而,一些患者会出现疾病复发。本研究旨在确定pT1N+或pT2-3N0胃癌复发的危险因素。

患者与方法

本研究纳入了2001年1月至2020年12月期间在我院接受根治性胃切除术的157例诊断为pT1N+或pT2-3N0胃癌的患者。获取了临床病理数据和手术数据。使用Cox比例风险回归模型分析独立预后因素。

结果

13例患者(8.3%)出现疾病复发。多因素分析显示,检查淋巴结数量是无复发生存的独立预后因素(风险比=10.90;95%置信区间=1.39-85.86;p=0.023)。检查淋巴结数量≤35个的组与检查淋巴结数量≥36个的组相比,无复发生存率显著更差(80.7%对98.7%;p=0.0005)。

结论

检查淋巴结数量(≤35个)是pT1N+或pT2-3N0胃癌根治性胃切除术后复发的独立危险因素。

相似文献

本文引用的文献

1
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition).日本胃癌治疗指南 2021(第 6 版)。
Gastric Cancer. 2023 Jan;26(1):1-25. doi: 10.1007/s10120-022-01331-8. Epub 2022 Nov 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验